The connection between aging and immune dysfunction is uncovering how immunoaging processes contribute to disease. Recent data from Alzheimer’s disease, Parkinson’s disease, and adult and pediatric glioblastomas reveal a novel role for TIM3 in brain immune alteration. These findings highlight the role of TIM3 in promoting myeloid cell dysfunction toward an immunosuppressive profile. TIM3-blocking antibody treatments for central nervous system pathologies could be a new therapeutic window for healthcare systems.
Segura-Collar et al. (Fri,) studied this question.